We founded a charitable organisation dedicated to improving treatment outcomes for children diagnosed with diffuse intrinsic pontine glioma (DIPG). DIPG is the deadliest form of childhood cancer with an average survival rate of just nine months following diagnosis.
We are RUN DIPG.
We fund critical medical research into DIPG, coordinated by Dr Matt Dun, a cancer researcher at the Hunter Medical Research Institute (HMRI) and the University of Newcastle, whose daughter Josephine was diagnosed with DIPG in 2018. Our researchers are focused on investigating ways to identify and characterise markers of disease progression, testing new drug therapies, and designing treatment strategies to improve survival rates. We actively profile DIPG tumours using sophisticated technologies, which enables us to identify how each DIPG grows and survives, revealing targets for improved treatments.
To find out more head over to the RUNDIPG.org site